PharmTech News

Articles

GSK has received a positive recommendation from the EMA’s CHMP for Nucala (mepolizumab) to be used as a treatment in three additional eosinophil-driven diseases.

GSK Receives Positive Opinion from CHMP for Nucala

Celltrion Group has been granted approval for regdanvimab (CT-P59) to be used as a treatment for COVID-19 by the Korean Ministry of Food and Drug Safety (MFDS). 

Celltrion Gains Regulatory Nod in Korea for Regdanvimab

In an amendment to their existing contract manufacturing agreement, Celsian and Poly Pharm expand GEN-1 program collaboration to add clinical and commercial batches of investigational vaccine.

Celsion and Poly Pharm to Manufacture Celsion’s DNA-Based Vaccine

New data finds J&J COVID-19 vaccine and booster to provide increased protection against COVID-19. 

Real-World Evidence Shows Strong Protection from COVID-19 with J&J Vaccine and Booster

Celularity and Oncternal’s collaboration will focus on therapeutics targeting Orphan Receptor 1, which is linked to aggression and survival in solid tumor cells.

Celularity and Oncternal Therapeutics to Research Placental-Derived Cellular Therapies

Lonza’s investment in its Stein and Basel facilities in Switzerland aims to expand its overall drug product development and manufacturing services.

Lonza to Expand Capabilities at Manufacturing Sites in Switzerland

Novartis’ acquisition of Arctos Medical could lead to significant advancements in optogenetic therapies for patients with vision loss.

Novartis Acquires Arctos Medical, Expanding Optogenetics Profile

Metrion’s new 12,000 ft² headquarters will significantly expand its range of services and cell lines.

Metrion Biosciences Relocates to New Headquarters

The topline data from Pfizer and BioNTech’s trial suggests that a 10 µg vaccine is safe and effective among the 5 to 11 age group.

 Pfizer and BioNTech Announce Positive Results In COVID-19 Vaccine Trial for Children Ages 5 to 11

Moderna’s newest insights include an overall efficacy review, a study on breakthrough infections, and a study on long-term immunity.

Bio/Pharma News